- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
17
High return on equity, past performance and sound balance sheet.
17 companies
Rigel Pharmaceuticals
Market Cap: US$740.2m
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
RIGL
US$40.78
7D
-16.6%
1Y
115.7%
Medpace Holdings
Market Cap: US$15.9b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$557.90
7D
1.8%
1Y
61.3%
Illumina
Market Cap: US$20.8b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$134.87
7D
4.6%
1Y
-6.3%
ACADIA Pharmaceuticals
Market Cap: US$4.5b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$27.15
7D
-1.1%
1Y
57.3%
Catalyst Pharmaceuticals
Market Cap: US$2.8b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$23.62
7D
0.4%
1Y
10.5%
Exelixis
Market Cap: US$11.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$40.88
7D
-7.8%
1Y
16.7%
Waters
Market Cap: US$23.4b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$385.33
7D
-2.4%
1Y
1.9%
Harmony Biosciences Holdings
Market Cap: US$2.3b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$40.51
7D
1.7%
1Y
25.1%
Incyte
Market Cap: US$18.9b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$95.41
7D
-6.9%
1Y
39.2%
CytomX Therapeutics
Market Cap: US$709.9m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$4.19
7D
6.1%
1Y
277.5%
Champions Oncology
Market Cap: US$86.9m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.72
7D
11.3%
1Y
6.2%
Niagen Bioscience
Market Cap: US$531.0m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$6.52
7D
1.1%
1Y
6.5%
ADMA Biologics
Market Cap: US$4.9b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$19.78
7D
-0.4%
1Y
6.4%
BioStem Technologies
Market Cap: US$71.5m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.14
7D
4.7%
1Y
-75.9%
Puma Biotechnology
Market Cap: US$288.7m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.86
7D
10.6%
1Y
103.5%
Oramed Pharmaceuticals
Market Cap: US$120.8m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.07
7D
14.1%
1Y
24.3%
Aurinia Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
AUPH
US$15.85
7D
1.5%
1Y
69.2%